Be the first person to write a business review for Sucampo Pharmaceuticals, Inc.

SuperGen was founded in 1991 and is based in Dublin, California. SuperGen, Inc., a pharmaceutical company, engages in the discovery, development, and commercialization of therapies to treat patients with cancer. The company licensed its new drug application approved product, Dacogen for the treatment of patients with myelodysplastic syndromes. It primarily focuses on developing MP-470, a DNA repair suppressor; SGI-1776, a PIM kinase inhibitor; MP-529, an Aurora kinase inhibitor; SGI-110, a DNMT1 inhibitor; and SGI-1252, a JAK2 inhibitor. SuperGen also has an approved product, Mitozytrex for the treatment of solid tumors. In addition, the company is developing Orathecin, a Phase III clinical trial product for the treatment of solid tumors; Partaject busulfan, a Phase I/II clinical trial product for neoplastic meningitis/bone marrow transplant; Partaject Orathecin, a non-clinical stage product for the treatment of solid tumors; and CZ 112, a Phase I clinical trial product for the treatment of solid tumors. It is also developing Cremophor-free paclitaxel, a non-clinical stage product for the treatment of solid tumors; Avicine, a therapeutic vaccine for the treatment of cancer, which is in Phase II trial; VEGF, a non-clinical stage product for the treatment of anti-angiogenesis; PZG, a Phase II clinical trial product for the treatment of type II diabetes; and AM454, a phosphocholine derivative, which is in non-clinical stage for obesity/diabetes. The company sells its products to clinics, hospitals, hospital buying groups, drug distributors, and wholesalers in the United States and Europe. It has a collaboration agreement with GlaxoSmithKline Inc. to discover and develop cancer therapeutics based on epigenetic targets.

Telik, Inc. company was founded in 1988 and is based in Palo Alto, California. Telik, Inc., a clinical stage drug development company, focuses on discovering and developing small molecule drugs to treat cancer and inflammatory diseases. Telik company's advanced investigational drug candidates in clinical development are TELINTRA, a modified glutathione analog for the treatment of cytopenias due to myelodysplastic syndrome or chemotherapy, and TELCYTA, a tumor-activated prodrug for the treatment of advanced ovarian cancer and non-small cell lung cancer. Telik's product candidates were discovered using its proprietary drug discovery technology, TRAP, which enables the discovery of small molecule drug candidates.

Teva Pharmaceutical Industries Limited company was founded in 1901 and is headquartered in Petach Tikva, Israel. Teva Pharmaceutical Industries Limited (Teva) is a global pharmaceutical company that develops, produces and markets generic drugs covering all treatment categories. The Company has a pharmaceutical business, whose principal products are Copaxone for multiple sclerosis and Azilect for Parkinson’s disease and respiratory products. Teva’s active pharmaceutical ingredient business provides vertical integration to Teva’s own pharmaceutical production and sells to third party manufacturers. The Company’s global operations are conducted in North America, Europe, Latin America, Asia and Israel. Teva has operations in more than 60 countries, as well as 38 finished dosage pharmaceutical manufacturing sites in 17 countries, 20 generic research and development centers operating mostly within certain manufacturing sites and 20 API manufacturing sites around the world. In January 2009, Phibro Animal Health Corporation completed the acquisition of the Abic Animal Health business from the Company.

The Medicines Company was founded in 1996 and is based in Parsippany, New Jersey. The Medicines Company, a pharmaceutical company, provides medicines for the treatment of critical care patients worldwide. It markets Angiomax, an intravenous direct thrombin inhibitor for use as an anticoagulant in combination with aspirin in patients with unstable angina undergoing percutaneous transluminal coronary angioplasty; and Cleviprex, a dihydropyridine calcium channel blocker, for the control of high blood pressure. The company's development products include cangrelor, an injectable antiplatelet agent that prevents platelet activation and aggregation in the clotting process; Oritavancin, a semi-synthetic lipoglycopeptide antibiotic for the treatment of gram-positive infections; and CU-2010 for the prevention of blood loss during surgery. Its customers include hospital management, physicians, hospital pharmacists, nurses, and other care staff. The Medicines Company sells its products through sales representatives and managers. The company has commercial supply agreement with Lonza Braine S.A. for the development and supply of the Angiomax bulk drug substance.

Unigene Laboratories, Inc. company was founded in 1980 and is based in Boonton, New Jersey. Unigene Laboratories, Inc., a biopharmaceutical company, engages in the research, production, and delivery of peptides for medical use primarily in the United States. The company focuses on the development of calcitonin and other peptide products for the treatment of osteoporosis and other indications, including nasal and oral calcitonin, and oral parathyroid hormone (PTH). It offers Fortical, a nasal calcitonin product for the treatment of postmenopausal osteoporosis. Unigene Laboratories has licensing agreements with GlaxoSmithKline to develop an oral formulation of an analog of PTH; Upsher-Smith Laboratories, Inc. to market Fortical; Novartis Pharma AG to manufacture calcitonin; and Shijiazhuang Pharmaceutical Group for research, development, and manufacture of recombinant salmon calcitonin and non-oral PTH.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.